Embecta Corp.

NasdaqGS:EMBC 株式レポート

時価総額：US$541.9m

Embecta バランスシートの健全性

財務の健全性 基準チェック /16

Embectaの総株主資本は$-613.1M 、総負債は$1.4Bで、負債比率は-222.2%となります。総資産と総負債はそれぞれ$1.1Bと$1.7Bです。 Embectaの EBIT は$325.1Mで、利息カバレッジ比率3.1です。現金および短期投資は$201.3Mです。

主要情報

-222.22%

負債資本比率

US$1.36b

負債

インタレスト・カバレッジ・レシオ3.1x
現金US$201.30m
エクイティ-US$613.10m
負債合計US$1.68b
総資産US$1.06b

財務の健全性に関する最新情報

Recent updates

EMBC: Wound Care Expansion Will Support Future Upside Despite Lower Price Targets

Analysts have trimmed their targets on Embecta by $2 to $3, citing updated expectations that align with an unchanged fair value estimate of $15, a steady discount rate of 12.33%, and consistent long term assumptions for revenue trends, profit margin, and a future P/E of about 7.9x. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed fair value estimate of $15 and implied P/E of about 7.9x as leaving room for the share price to close part of the gap if execution on the existing plan remains consistent.

EMBC: Higher Discount Rate And Wound Care Expansion Will Support Future Upside

Analysts have adjusted Embecta's implied fair value price target from $16.67 to $15.00, reflecting updated views on discount rates, revenue trends, profit margins and future P/E assumptions following recent research, including price target cuts from both Mizuho and BTIG. Analyst Commentary Recent research updates point to a more cautious stance on Embecta, with the lower implied fair value aligning with trimmed price targets and more conservative assumptions around growth, profitability and P/E levels.

Embecta: An Interesting Deal At An Interesting Time

Mar 19

EMBC: Future M&A And Margin Pressures Will Shape Balanced Outlook

Analysts have maintained Embecta's price target at $11.00, citing updated assumptions that include a slightly lower discount rate, softer revenue growth expectations, a reduced profit margin outlook, and a higher future P/E multiple. What's in the News Embecta is actively exploring mergers and acquisitions, with leadership emphasizing a focus on chronic care drug delivery where the company can use its manufacturing strengths and growing B2B channel (Key Developments).

Embecta's (NASDAQ:EMBC) Solid Earnings Have Been Accounted For Conservatively

Feb 12
Embecta's (NASDAQ:EMBC) Solid Earnings Have Been Accounted For Conservatively

Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 09
Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15

Feb 08
Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15

EMBC: Future M&A Plans Will Test Balance Sheet And Earnings Multiple

Analysts now hold their fair value estimate for Embecta at US$11.00. The unchanged target reflects modest tweaks to assumptions around revenue growth, profit margin and future P/E that offset the slightly higher discount rate.

EMBC: Future M&A Ambitions Will Heighten Risk Against Weak Earnings Multiple

Analysts have kept their fair value estimate for Embecta steady at US$11.00 while slightly adjusting underlying assumptions around discount rate, revenue growth, profit margins, and forward P/E. This reflects updated views on the company’s risk profile and earnings power without a change to the headline target.

Market Cool On Embecta Corp.'s (NASDAQ:EMBC) Earnings

Jan 09
Market Cool On Embecta Corp.'s (NASDAQ:EMBC) Earnings

EMBC: Medium Term Guidance Will Balance Revenue Outlook With Margin Pressures

Analysts have modestly trimmed their price target on Embecta to 11.00 dollars, reflecting slightly higher discount rate assumptions and a marginally lower anticipated future P or E multiple, partially offset by incrementally stronger expectations for revenue growth and profit margins. What's in the News Embecta issued new fiscal 2026 guidance, projecting reported revenues between 1,071 million and 1,093 million dollars, signaling confidence in its medium term growth trajectory (Key Developments).

EMBC: Outlook Will Balance Stabilizing Revenues With Pressured Profit Margins Through 2026

Analysts have modestly raised their price target on Embecta to 11.00 dollars from 11.00 dollars. This reflects improved expectations for a return to positive revenue growth and a higher future earnings multiple, partially offset by a higher discount rate and slightly lower projected profit margins.

US$16.67: That's What Analysts Think Embecta Corp. (NASDAQ:EMBC) Is Worth After Its Latest Results

Nov 28
US$16.67: That's What Analysts Think Embecta Corp. (NASDAQ:EMBC) Is Worth After Its Latest Results

Is Now The Time To Look At Buying Embecta Corp. (NASDAQ:EMBC)?

Nov 01
Is Now The Time To Look At Buying Embecta Corp. (NASDAQ:EMBC)?

Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 99% Above Its Share Price

Sep 26
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 99% Above Its Share Price

Even With A 29% Surge, Cautious Investors Are Not Rewarding Embecta Corp.'s (NASDAQ:EMBC) Performance Completely

Aug 28
Even With A 29% Surge, Cautious Investors Are Not Rewarding Embecta Corp.'s (NASDAQ:EMBC) Performance Completely

GLP-1 Partnerships Will Expand Global Healthcare Reach

The consensus price target for Embecta has been cut from $18.33 to $16.00, primarily reflecting lowered revenue growth forecasts and a declining future P/E multiple. What's in the News Embecta Corp.

Sentiment Still Eluding Embecta Corp. (NASDAQ:EMBC)

Jul 04
Sentiment Still Eluding Embecta Corp. (NASDAQ:EMBC)

Embecta (NASDAQ:EMBC) Has Announced A Dividend Of $0.15

May 22
Embecta (NASDAQ:EMBC) Has Announced A Dividend Of $0.15

What Is Embecta Corp.'s (NASDAQ:EMBC) Share Price Doing?

May 09
What Is Embecta Corp.'s (NASDAQ:EMBC) Share Price Doing?

Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 87% Above Its Share Price

Mar 06
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 87% Above Its Share Price

Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour

Feb 28

New Initiatives Expected To Make Embecta More Profitable

Dec 04

Embecta (NASDAQ:EMBC) Is Due To Pay A Dividend Of $0.15

Nov 29
Embecta (NASDAQ:EMBC) Is Due To Pay A Dividend Of $0.15

At US$16.33, Is It Time To Put Embecta Corp. (NASDAQ:EMBC) On Your Watch List?

Nov 07
At US$16.33, Is It Time To Put Embecta Corp. (NASDAQ:EMBC) On Your Watch List?

It's A Story Of Risk Vs Reward With Embecta Corp. (NASDAQ:EMBC)

Sep 24
It's A Story Of Risk Vs Reward With Embecta Corp. (NASDAQ:EMBC)
User avatar

Expanding Global Leadership In Insulin Devices Fuels Revenue Growth And Operational Efficiencies

Strengthening the base business in insulin injection devices suggests potential for stable, growing revenues as the global demographic needing these devices increases.

Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15

Aug 16
Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15

Embecta Corp. Just Beat EPS By 79%: Here's What Analysts Think Will Happen Next

Aug 14
Embecta Corp. Just Beat EPS By 79%: Here's What Analysts Think Will Happen Next

When Should You Buy Embecta Corp. (NASDAQ:EMBC)?

Jul 13
When Should You Buy Embecta Corp. (NASDAQ:EMBC)?

Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

May 12
Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Embecta's (NASDAQ:EMBC) Dividend Will Be $0.15

Feb 21
Embecta's (NASDAQ:EMBC) Dividend Will Be $0.15

財務状況分析

短期負債: EMBCは マイナスの株主資本 を有しており、これは 短期資産 が 短期負債 をカバーしていないことよりも深刻な状況です。

長期負債: EMBCは株主資本がマイナスであり、これは短期資産が 長期負債 をカバーしていないことよりも深刻な状況です。

デット・ツー・エクイティの歴史と分析

負債レベル: EMBCは 株主資本がマイナス となっており、これは高い負債レベルよりも深刻な状況です。

負債の削減: EMBCの株主資本はマイナスなので、時間の経過とともに負債が減少したかどうかを確認する必要はありません。

債務返済能力: EMBCの負債は 営業キャッシュフロー によって 十分にカバーされていません ( 15.7% )。

インタレストカバレッジ: EMBCの負債に対する 利息支払い は EBIT ( 3.1 x coverage) によって 十分にカバーされています。

貸借対照表

健全な企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/01 02:43
終値2026/05/01 00:00
収益2025/12/31
年間収益2025/09/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Embecta Corp. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7

アナリスト機関
Travis SteedBofA Global Research
Travis SteedBofA Global Research
Michael GormanBTIG